p-nitrophenyl(1,2,3,4-tetrahydroquinoline)carbamate | 191932-19-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: p-nitrophenyl(1,2,3,4-tetrahydroquinoline)carbamate
• 英文别名: 4-nitrophenyl 3,4-dihydroquinoline-1(2H)-carboxylate；(4-nitrophenyl) 3,4-dihydro-2H-quinoline-1-carboxylate
• CAS: 191932-19-1
• 化学式: C₁₆H₁₄N₂O₄
• 分子量: 298.298
• InChiKey: NOKHSGUJEWXYLK-UHFFFAOYSA-N

物化性质

• 沸点：
  462.8±45.0 °C(predicted)
• 密度：
  1.341±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  p-nitrophenyl(1,2,3,4-tetrahydroquinoline)carbamate 、 4-(1H-吡唑-4-基)哌啶 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以28%的产率得到(3,4-Dihydro-2H-quinolin-1-yl)[4-(1H-pyrazol-4-yl)piperidin-1-yl]methanone
  参考文献：
  名称：

  Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11β-hydroxysteroid-dehydrogenase type 1

  摘要：

  A High Throughput Screening campaign allowed the identification of a novel class of ureas as 11 beta-HSD1 inhibitors. Rational chemical optimization provided potent and selective inhibitors of both human and murine 11 beta-HSD1 with an appropriate ADME profile and ex vivo activity in target tissues. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.111
• 作为产物：
  描述：

  1,2,3,4-四氢喹啉 、 对硝基苯基氯甲酸酯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 p-nitrophenyl(1,2,3,4-tetrahydroquinoline)carbamate
  参考文献：
  名称：

  DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE

  摘要：

  本发明涉及一种具有以下式（I）的化合物： 其中i、j、n、o、p、q、r、R1a、R1b、R1c、R1d、R2a、R2b、R2c、R2d、R3a、R3b和R4如本文所定义，或其与酸的加合盐，或其水合物或溶剂合物，其制备、药物组合物以及用于治疗11β-HSD1酶参与的疾病的用途。

  公开号：

  US20090176775A1
• 作为试剂：
  描述：

  1,2,3,4-四氢喹啉 、 三乙胺 、 对硝基苯基氯甲酸酯 在 盐酸 、 magnesium sulfate 、 p-nitrophenyl(1,2,3,4-tetrahydroquinoline)carbamate 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以to result in 21.5 g of 4-nitrophenyl 3,4-dihydroquinoline-1(2H)-carboxylate的产率得到p-nitrophenyl(1,2,3,4-tetrahydroquinoline)carbamate
  参考文献：
  名称：

  DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE

  摘要：

  本发明涉及式（I）的化合物：其中i，j，n，o，p，q，r，R1a，R1b，R1c，R1d，R2a，R2b，R2c，R2d，R3a，R3b和R4如本文所定义，或其与酸的加合盐，或其水合物或溶剂化物，其制备方法，制药组合物以及用于治疗与酶11β-HSD1有关的疾病的用途。

  公开号：

  US20090176775A1

文献信息

• Melanin-concentrating hormone antagonist
  申请人：——

  公开号：US20030158177A1

  公开（公告）日：2003-08-21

  A melanin-concentrating hormone antagonist comprising a compound of the formula: 1 wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms; Y is a spacer having a main chain of 1 to 6 atoms; ring A is benzene ring which may be further substituted; ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted; R 1 and R 2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; or R 1 and R 2 , together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R 2 , together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or a salt thereof is useful as a preventive or therapeutic agent for obesity, etc.

  一种黑素浓缩激素拮抗剂，包括以下结构的化合物：其中R是氢原子或可能被取代的环状基团；X是具有1到10个原子主链的键或间隔物；Y是具有1到6个原子主链的间隔物；环A是苯环，可能进一步被取代；环B是一个含氮的非芳香杂环环，成员数为5到9，可能进一步被取代；R1和R2相同或不同，是氢原子、可能被取代的烃基或可能被取代的杂环基；或者R1和R2，与相邻的氮原子一起，可以形成一个可能被取代的含氮杂环环；或者R2，与相邻的氮原子和Y一起，可以形成一个可能被取代的含氮杂环环；或其盐可用作肥胖等疾病的预防或治疗剂。
• Aryl sulfonamides and sulfamide derivatives and uses thereof
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20030013714A1

  公开（公告）日：2003-01-16

  This invention is directed to novel aryl sulfonamide and sulfamide compounds which bind selectively to and inhibit the activity of the human Y5 receptor. This invention is also related to uses of these compounds for the treatment of feeding disorders such as obesity, anorexia nervosa, bulimia nervosa, and abnormal conditions such as sexual/reproductive disorders, depression, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure or sleep disturbances and for the treatment of any disease in which antagonism of a Y5 receptor may be useful.

  本发明涉及新型芳基磺酰胺和磺酰胺化合物，其选择性地结合并抑制人类Y5受体的活性。本发明还涉及这些化合物在治疗进食障碍，如肥胖症、厌食症、贪食症和异常情况，如性/生殖障碍、抑郁症、癫痫发作、高血压、脑出血、充血性心力衰竭或睡眠障碍等方面的用途，以及在治疗任何可能有用的Y5受体拮抗作用的疾病方面的用途。
• Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators
  申请人：Sanofi-Aventis

  公开号：US07947834B2

  公开（公告）日：2011-05-24

  The present invention is related to a compound of formula (I): wherein i, j, n, o, p, q, r, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b and R4 are as defined herein, or an addition salt with an acid thereof, or a hydrate or solvate thereof, its preparation, pharmaceutical composition, and uses for treating a disease in which the enzyme 11β-HSD1 is involved.

  本发明涉及式（I）的化合物：其中i、j、n、o、p、q、r、R1a、R1b、R1c、R1d、R2a、R2b、R2c、R2d、R3a、R3b和R4如本文所定义的，或其与酸的加成盐，或其水合物或溶剂化物，其制备方法、药物组合物以及用于治疗酶11β-HSD1参与的疾病的用途。
• MELANIN-CONCENTRATING HORMONE ANTAGONIST
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1283199A1

  公开（公告）日：2003-02-12

  A melanin-concentrating hormone antagonist comprising a compound of the formula: wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms; Y is a spacer having a main chain of 1 to 6 atoms; ring A is benzene ring which may be further substituted; ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted; R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or a salt thereof is useful as a preventive or therapeutic agent for obesity, etc.

  一种黑色素浓缩激素拮抗剂，包括式中化合物： 其中 R 是氢原子或可被取代的环状基团；X 是主链为 1 至 10 个原子的键或间隔物；Y 是主链为 1 至 6 个原子的间隔物；环 A 是可被进一步取代的苯环；环 B 是可被进一步取代的 5 至 9 元含氮非芳香杂环；R1和R2相同或不同，且为氢原子、可被取代的烃基或可被取代的杂环基；或R1和R2连同相邻的氮原子可形成可被取代的含氮杂环；或R2连同相邻的氮原子和Y可形成可被取代的含氮杂环；或其盐可用作肥胖症等的预防或治疗剂。
• DÉRIVÉS D'URÉES DE PIPERIDINE OU PYRROLIDINE, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
  申请人：Sanofi-Aventis

  公开号：EP2044057A2

  公开（公告）日：2009-04-08